342 related articles for article (PubMed ID: 22127320)
1. What is the potential for thrombopoietic agents in acute leukemia?
Kuter DJ
Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
[TBL] [Abstract][Full Text] [Related]
2. New thrombopoietic growth factors.
Kuter DJ
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S347-56. PubMed ID: 19778863
[TBL] [Abstract][Full Text] [Related]
3. The new thrombopoietic agenda: impact on leukemias and MDS.
Bussel JB
Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
[TBL] [Abstract][Full Text] [Related]
4. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Neunert CE
Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
10. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
12. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
[No Abstract] [Full Text] [Related]
13. Thrombopoietic agents.
Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
[TBL] [Abstract][Full Text] [Related]
14. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
15. New thrombopoietin receptor agonists for platelet disorders.
Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
[TBL] [Abstract][Full Text] [Related]
16. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
[TBL] [Abstract][Full Text] [Related]
17. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
19. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
[Next] [New Search]